Kurzfassung

A randomized, double-blind, multi-center, parallel-goup, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis subjects with severe pruritus receicing topical corticosteroids